Intercept Announces New Data Showing Potential of Fixed-Dose Combination of OCA and Bezafibrate to Normalize Multiple Biomarkers in PBC to be Featured in Podium Presentation at EASL Congress 2023

Interim analysis of ongoing Phase 2 study shows combination of OCA 5-10 mg + bezafibrate 400 mg improved levels of multiple biochemical markers associated with clinical outcomes in PBC including ALP,... | June 7, 2023

Related Keywords

United States ,Vienna ,Wien ,Austria ,Antonio Civitarese ,Karen Preble ,Frederik Nevens ,Alexandre Louvet ,Lynda Szczech ,Nareg Sagherian ,M Michelle Berrey ,Cheng Zou ,Vaclav Hejda ,Research Development ,Linkedin ,Globenewswire Inc ,Company On Twitter ,Intercept Pharmaceuticals Inc ,European Association For The Study ,Nasdaq ,Global Corporate Communications ,International Normalized Ratio ,Michelle Berrey ,Chief Medical Officer ,Planned Interim Analysis ,Active Controlled Trial Evaluating ,Obeticholic Acid ,Serum Biomarkers ,Primary Biliary ,Bezafibrate Fixed Dose ,Important Safety Information ,Narrow Therapeutic ,Bile Salt Efflux ,Full Prescribing Information ,Intercept Pharmaceuticals ,Executive Director ,Global Investor ,Nc Stock Exchange ,News ,Information ,Press Release ,Interim ,Analysis ,F ,Ngoing ,Hase , ,Study ,Shows ,Combination ,Ca ,G ,Bezafibrate ,00 ,Mproved ,Levels ,Multiple ,Biochemical ,Markers ,Ssociated ,Ith ,Linical ,Outcomes ,N ,Abc ,Ncluding Icpt Us45845p1084 ,